Alan Burnett, MD, University of Glasgow, Glasgow, UK, comments on the standard treatment of elderly and frail patients with acute myeloid leukemia (AML), highlighting some of the challenges in evaluating IDH inhibitors in clinical trials in younger patients with AML. According to Dr Burnett, it is important to determine the optimal dosing schedule for the combination of azacitidine and venetoclax instead of investigating triplet therapies that may lead to higher toxicity. Moving foward, Dr Burnett notes that while IDH inhibitors have demonstrated efficacy in elderly patients, evaluating their efficacy in younger patients poses a challenge due to difficulty in recruiting large numbers of patients for clinical trials. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
